ATE517895T1 - Harminderivate, bei deren herstellung verwendete zwischenprodukte, herstellungsverfahren und verwendung davon - Google Patents

Harminderivate, bei deren herstellung verwendete zwischenprodukte, herstellungsverfahren und verwendung davon

Info

Publication number: ATE517895T1
Authority: AT; Austria
Prior art keywords: production; intermediate products; products used; compounds; medicines
Prior art date: 2003-06-02

Application number

AT04735720T

Other languages

English (en)

Inventor

Jialin Wu

Qi Chen

Rihui Cao

F Yu

Zihou Wang

Wenlie Peng

Original Assignee

Xinjiang Huashidan Pharmaceutical Res Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-06-02

Filing date

2004-06-02

Publication date

2011-08-15

2004-06-02 Application filed by Xinjiang Huashidan Pharmaceutical Res Co Ltd filed Critical Xinjiang Huashidan Pharmaceutical Res Co Ltd

2011-08-15 Application granted granted Critical

2011-08-15 Publication of ATE517895T1 publication Critical patent/ATE517895T1/de

Links

238000004519 manufacturing process Methods 0.000 title abstract 3
BXNJHAXVSOCGBA-UHFFFAOYSA-N Harmine Chemical class N1=CC=C2C3=CC=C(OC)C=C3NC2=C1C BXNJHAXVSOCGBA-UHFFFAOYSA-N 0.000 title abstract 2
239000013067 intermediate product Substances 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 2
229940079593 drug Drugs 0.000 abstract 2
239000003814 drug Substances 0.000 abstract 2
238000002360 preparation method Methods 0.000 abstract 2
206010028980 Neoplasm Diseases 0.000 abstract 1
230000000259 anti-tumor effect Effects 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
239000000543 intermediate Substances 0.000 abstract 1
230000004048 modification Effects 0.000 abstract 1
238000012986 modification Methods 0.000 abstract 1
210000000653 nervous system Anatomy 0.000 abstract 1
238000001126 phototherapy Methods 0.000 abstract 1
238000001959 radiotherapy Methods 0.000 abstract 1
230000001988 toxicity Effects 0.000 abstract 1
231100000419 toxicity Toxicity 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT04735720T 2003-06-02 2004-06-02 Harminderivate, bei deren herstellung verwendete zwischenprodukte, herstellungsverfahren und verwendung davon ATE517895T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CNB031364063A CN100503607C (zh)	2003-06-02	2003-06-02	去氢骆驼蓬碱衍生物类化合物及其应用
PCT/CN2004/000591 WO2004106335A1 (en)	2003-06-02	2004-06-02	Harmine derivatives, intermediates used in their preparation, preparation processes and use thereof

Publications (1)

Publication Number	Publication Date
ATE517895T1 true ATE517895T1 (de)	2011-08-15

Family

ID=33480390

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04735720T ATE517895T1 (de)	2003-06-02	2004-06-02	Harminderivate, bei deren herstellung verwendete zwischenprodukte, herstellungsverfahren und verwendung davon

Country Status (6)

Country	Link
US (1)	US8772311B2 (de)
EP (1)	EP1634881B1 (de)
JP (1)	JP5128812B2 (de)
CN (1)	CN100503607C (de)
AT (1)	ATE517895T1 (de)
WO (1)	WO2004106335A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE102007009264A1 (de) *	2007-02-26	2008-08-28	Ellneuroxx Ltd.	9-Alkyl-ß-Carboline zur Behandlung von neurodegenerativen Erkrankungen
WO2009038764A1 (en) *	2007-09-20	2009-03-26	D2E, Llc	Fluoro-containing derivatives of hydrogented pyrido[4,3-b]indoles with neuroprotective and cognition enhancing properties, process for preparing, and use
CN101429198B (zh) *	2007-11-09	2013-10-23	新疆华世丹药物研究有限责任公司	去氢骆驼蓬碱衍生物及其应用
CN102369021B (zh)	2008-12-19	2016-09-07	宏观基因有限公司	共价双抗体及其用途
US8362277B2 (en)	2009-01-09	2013-01-29	Board Of Regents Of The University Of Texas System	Pro-neurogenic compounds
US9162980B2 (en)	2009-01-09	2015-10-20	Board Of Regents Of The University Of Texas System	Anti-depression compounds
US9962368B2 (en)	2009-01-09	2018-05-08	Board Of Regents Of The University Of Texas System	Pro-neurogenic compounds
JP5766614B2 (ja)	2009-01-09	2015-08-19	ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システムＴｈｅＢｏａｒｄＯｆＲｅｇｅｎｔｓＯｆＴｈｅＵｎｉｖｅｒｓｉｔｙＯｆＴｅｘａｓＳｙｓｔｅｍ	神経新生促進化合物
CN102146080B (zh) *	2010-02-10	2013-01-30	新疆华世丹药业股份有限公司	β-咔啉碱衍生物类化合物及其应用
WO2011133795A2 (en) *	2010-04-22	2011-10-27	The Brigham And Women's Hospital, Inc.	Beta-carbolines as inhibitors of haspin and dyrk kinases
US9168247B2 (en)	2010-06-25	2015-10-27	Facultes Universitaires Notre Dame De La Paix	Beta carboline derivatives useful in the treatment of proliferative disorders
AU2011274787B2 (en)	2010-07-07	2016-06-16	Board Of Regents Of The University Of Texas System	Pro-neurogenic compounds
US20130165474A1 (en) *	2010-08-17	2013-06-27	Travis Dunckley	Compounds that inhibit tau phosphorylation
CN102952151B (zh) *	2011-08-31	2017-07-28	新疆华世丹药物研究有限责任公司	3位双β‑咔啉碱类化合物、其制法和其药物组合物与用途
CN103070862A (zh) *	2011-10-25	2013-05-01	新疆华世丹药物研究有限责任公司	去氢骆驼蓬碱衍生物在制备抗菌药物中的应用
AU2013305591B2 (en)	2012-08-24	2017-04-13	Board Of Regents Of The University Of Texas System	Pro-neurogenic compounds
US10011614B2 (en) *	2012-11-26	2018-07-03	Xinjiang Huashidan Pharmaceutical Research Co., Ltd	Bis-β-carboline compound and preparation method, pharmaceutical composition and use thereof
CN102977096B (zh) *	2012-12-07	2014-12-17	中国药科大学	具有靶向特性的去氢骆驼蓬碱衍生物的抗肿瘤前药
WO2015070237A1 (en)	2013-11-11	2015-05-14	Board Of Regents Of The University Of Texas System	Neuroprotective chemicals and methods for identifying and using same
WO2015070234A2 (en)	2013-11-11	2015-05-14	Board Of Regents Of The University Of Texas System	Neuroprotective compounds and use thereof
CN104744460B (zh) *	2013-12-30	2017-06-16	南开大学	β‑咔啉，二氢‑β‑咔啉和四氢‑β‑咔啉生物碱衍生物及其制备方法和在防治植物病毒、杀菌、杀虫方面的应用
CN103864787B (zh) *	2014-03-21	2015-11-18	河南师范大学	一种β-咔啉化合物的绿色合成方法
DK3188721T3 (da) *	2014-10-21	2019-08-12	Ankh Life Sciences Ltd	Humane terapeutika
US10092550B2 (en)	2014-10-21	2018-10-09	Ions Pharmaceutical S.À R.L.	Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof
US9907786B2 (en)	2014-10-21	2018-03-06	Ions Pharmaceutical S.À R.L.	Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
US20160106722A1 (en)	2014-10-21	2016-04-21	Life Plus, LLC	Human therapeutic agents
CN104557916B (zh) *	2014-12-03	2017-02-22	西北农林科技大学	2‑取代β‑咔啉类化合物及其用于制备预防或治疗肿瘤药物的应用
CN104530043B (zh) *	2014-12-03	2017-06-06	西北农林科技大学	9‑取代β‑咔啉类化合物及其用于制备预防或治疗肿瘤药物的应用
EP3321264A1 (de) *	2016-11-14	2018-05-16	Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft	Selektive inhibitoren der genotoxischen stressinduzierten ikk/nf-kb-pfade
CN106588918B (zh) *	2016-12-08	2019-02-19	广东省测试分析研究所（中国广州分析测试中心）	一种3-氨基-β-咔啉的制备方法及其应用
CN106977515A (zh) *	2017-04-13	2017-07-25	河北科技大学	β‑咔啉、γ‑咔啉衍生物、其制备方法及用途
CN111615509A (zh) *	2017-10-31	2020-09-01	赛特思H&B有限公司	具有信号转导与转录激活因子3抑制活性的化合物及其用途
US10947253B2 (en)	2019-08-05	2021-03-16	Ankh Life Sciences Limited	Fused polycyclic dimers
CN111362937B (zh) *	2020-03-06	2021-06-22	贵州医科大学	N-芳基-β-卡波林类衍生物及其用途
US12129265B2 (en)	2020-07-21	2024-10-29	Ankh Life Sciences Limited	Therapeutic agents and uses thereof
EP4185564A1 (de) *	2020-07-23	2023-05-31	Merck Patent GmbH	Tricyclische heterocyclen
CN113248498A (zh) *	2021-06-03	2021-08-13	河南沁朋科技有限公司	9H-吡啶[3,4-b]吲哚的合成新方法
CN114621225A (zh) *	2022-04-06	2022-06-14	石河子大学	一种咪唑并吡啶并吲哚类化合物及其制备方法、应用
CN115487184A (zh) *	2022-09-06	2022-12-20	南昌大学	去氢骆驼蓬碱在制备治疗结肠癌药物中的应用
US11897881B1 (en)	2023-07-31	2024-02-13	King Faisal University	Substituted pyrido[3,4-b]indole-3-carboxylic acids as CK2 inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES273769A1 (es) *	1961-01-18	1962-06-01	Geigy Ag J R	Procedimiento para la preparaciën de nuevos derivados de amidas de acido beta-carbolin-carboxilico
NZ194747A (en)	1979-08-29	1988-11-29	Schering Ag	9h-pyrido(3,4-b)indol-3-ylcarboxylic acid derivatives
US4317536A (en) *	1980-10-28	1982-03-02	Container Corporation Of America	Two-piece container
JPS57169481A (en) *	1981-04-13	1982-10-19	Otsuka Pharmaceut Co Ltd	Beta-carboline derivative
GB8330260D0 (en) *	1983-11-12	1983-12-21	Tanabe Seiyaku Co	Tetrahydro-beta-carboline derivatives
FR2555988A1 (fr) *	1983-12-06	1985-06-07	Centre Nat Rech Scient	Derive de b-carbolines, procede pour leurs preparations et medicament les contenant
KR20000005175A (ko)	1996-04-04	2000-01-25	프리돌린 클라우스너, 롤란드 비. 보레르	테트라하이드로-베타-카르볼린 유도체의 항전이제로서의 용도
DE19807993A1 (de)	1998-02-26	1999-09-02	Bayer Ag	Verwendung von ß-Carbolinderivaten zur Bekämpfung von TNF-alpha-abhängigen Krankheiten
CA2350887A1 (en)	1998-12-10	2000-06-15	Agouron Pharmaceuticals, Inc.	Non-peptide antagonists of glp-1 receptor and methods of use
EP1209158A1 (de)	2000-11-18	2002-05-29	Aventis Pharma Deutschland GmbH	Substitutierte beta-Carboline
GB0121941D0 (en)	2001-09-11	2001-10-31	Astrazeneca Ab	Chemical compounds
CN1160352C (zh) *	2001-12-19	2004-08-04	北京大学	具有抗HIV和抗癌活性的3-位取代的β-咔啉化合物，制备方法及其组合物和用途
WO2004067531A1 (en) *	2003-01-27	2004-08-12	Pfizer Inc.	Hiv-integrase inhibitors, pharmaceutical compositions, and methods for their use

2003
- 2003-06-02 CN CNB031364063A patent/CN100503607C/zh not_active Expired - Lifetime
2004
- 2004-06-02 WO PCT/CN2004/000591 patent/WO2004106335A1/zh not_active Ceased
- 2004-06-02 AT AT04735720T patent/ATE517895T1/de not_active IP Right Cessation
- 2004-06-02 US US10/559,824 patent/US8772311B2/en active Active
- 2004-06-02 EP EP04735720A patent/EP1634881B1/de not_active Expired - Lifetime
- 2004-06-02 JP JP2006508098A patent/JP5128812B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
EP1634881B1 (de)	2011-07-27
JP2006526580A (ja)	2006-11-24
CN100503607C (zh)	2009-06-24
WO2004106335A1 (en)	2004-12-09
US8772311B2 (en)	2014-07-08
EP1634881A4 (de)	2008-04-16
US20090227619A1 (en)	2009-09-10
WO2004106335A8 (en)	2006-03-09
JP5128812B2 (ja)	2013-01-23
EP1634881A1 (de)	2006-03-15
CN1552711A (zh)	2004-12-08

Legal Events

Date	Code	Title	Description
2012-01-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE517895T1 (de)	2011-08-15	Harminderivate, bei deren herstellung verwendete zwischenprodukte, herstellungsverfahren und verwendung davon
GB0305929D0 (en)	2003-04-23	Organic compounds
CY1114702T1 (el)	2016-10-05	Νεοι εναnτιομερως καθαροι βητα αγωνιστες, μεθοδος για την παραγωγη τους και χρηση αυτων ως φαρμακων
CY1107401T1 (el)	2012-12-19	Παραγωγα βενζοθειαζολιου πα την θεραπευτικη αντιμετωπιση της νοσου alzheimer και της νοσου parkinson
CY1111206T1 (el)	2015-06-11	Βενζοθειοφαινια υποκατεστημενα με πιπεραζινη για την αγωγη διανοητικων διαταραχων
DE60140708D1 (de)	2010-01-14	Prolinderivative und deren Verwendung als Medikamente
ATE490788T1 (de)	2010-12-15	Antivirale phosphonate analoge
CY1109644T1 (el)	2014-08-13	2,4-διαμινο-πυριμιδινες ως αναστολεις audora
WO2005023815A3 (en)	2005-07-21	Neuroprotective bicyclic compounds and methods for their use
DE502004012095D1 (de)	2011-02-17	Verfahren zum herstellen von 2-dihalogenacyl-3-amino-acryls ureestern und 3-dihalogenmethyl-pyrazol-4-carbons ureestern
DE60110415D1 (de)	2005-06-02	Neue Pyrazin-Derivate oder Salze davon, pharmazeutische Zusammensetzungen, die die Derivate oder deren Salze enthalten und Intermediäre zur Herstellung der Derivate
GB0313612D0 (en)	2003-07-16	Organic compounds
CY1116699T1 (el)	2017-03-15	Παραγωγα αλφα-αμινοαμιδιου τα οποια ειναι χρησιμα στην αγωγη γνωστικων διαταραχων
ATE525350T1 (de)	2011-10-15	Substituierte n-phenyl- bipyrrolidincarbonsäureamide und deren therapeutische verwendung
ECSP088541A (es)	2008-07-30	[(1h-indol-5-il)-heteroariloxi]-(1-aza-biciclo[3.3.1]nonanos como ligandos colinérgicos del n-achr para el tratamiento de trastornos psicóticos y neurodegenerativos
ATE347555T1 (de)	2006-12-15	6-aminomorphinanderivate, herstellungsverfahren dafür und deren verwendung
ATE479433T1 (de)	2010-09-15	Neue langwirksame beta-2-agonisten, und deren verwendung als arzneimittel
ATE542817T1 (de)	2012-02-15	Stickstoffhaltige heterocyclische verbindung und deren pharmazeutische verwendung
IL187001A0 (en)	2008-02-09	Preparation of (s)-4-fluromethyl-dihydro-furan -2-one
ATE482955T1 (de)	2010-10-15	Azabicyclooctan-3-onderivate und deren verwendung
ATE334680T1 (de)	2006-08-15	4-aminopiperidin-derivate, verfahren zur herstellung und ihre verwendung als arzneimittel
CY1118084T1 (el)	2017-06-28	ΠΑΡΑΓΩΓΑ ΤΟΥ 7-(ΕΤΕΡΟΑΡΥΛ-ΑΜΙΝΟ)-6,7,8,9-ΤΕΤΡΑΫΔΡΟΠΥΡΙΔΟ[1,2-α]ΙΝΔΟΛΟ ΟΞΙΚΟΥ ΟΞΕΟΣ ΚΑΙ Η ΧΡΗΣΗ ΤΟΥΣ ΩΣ ΤΡΟΠΟΠΟΙΗΤΕΣ ΤΟΥ ΥΠΟΔΟΧΕΑ ΤΗΣ ΠΡΟΣΤΑΓΛΑΝΔΙΝΗΣ D2
BRPI0519267A2 (pt)	2009-01-06	derivado de quinolina, seu uso, produÇço e medicamento contendo o mesmo
NI201000065A (es)	2010-09-13	CARBONO UNIDO A LOS MODULADORES DE LA y-SECRETASA.
UY27733A1 (es)	2003-10-31	Derivados de ciclopenteno.